Merged Businesses to Provide Cryotherapy and Brachytherapy

(Yokneam, Israel) has merged with the brachytherapy business of Amersham plc (Little Chalfont, UK), forming a new company called Oncura.

Oncura will operate as an independent business of Amersham plc, with Galil holding a minority position of 25%. The company is to be headquartered in Philadelphia (PA, USA) and will be an important provider of minimally invasive treatments for prostate cancer and kidney cancer. Oncura will provide SeedNet cryotherapy products, a unique range based on ultra-thin 17-gauge CryoNeedles, and will also provide Rapid Strand, OncoSeed, EchoSeed, and TheraSeed brachytherapy products. In addition, the company will co-promote the metastatic bone palliation agent, Metastron, of Amersham.

"Building on our base of complementary products, out goal is to develop a strong franchise in the management of urological diseases,” said James McGlone, former president of Galil Medical and now president and CEO of Oncura. "Patients deserve as many options as possible, and they deserve those that are the most minimally invasive.”





Related Links:
Gagil Medical
Amersham